{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T23:15:23Z","timestamp":1794352523556,"version":"4.9.0"},"reference-count":190,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T00:00:00Z","timestamp":1741046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473422"],"award-info":[{"award-number":["82473422"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016697","name":"Youth Innovation Technology Project of Higher School in Shandong Province","doi-asserted-by":"publisher","award":["tsqn202312349"],"award-info":[{"award-number":["tsqn202312349"]}],"id":[{"id":"10.13039\/100016697","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.biopha.2025.117955","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T18:31:17Z","timestamp":1741890677000},"page":"117955","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine"],"prefix":"10.1016","volume":"185","author":[{"given":"Cheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoran","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoqiu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6689-6135","authenticated-orcid":false,"given":"Fei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CU9.0000000000000145","article-title":"Prostate cancer screening: continued controversies and novel biomarker advancements","volume":"16","author":"Tidd-Johnson","year":"2022","journal-title":"Curr. Urol."},{"issue":"12","key":"10.1016\/j.biopha.2025.117955_bib2","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.biopha.2025.117955_bib3","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CU9.0000000000000245","article-title":"Leptomeningeal metastases in prostate cancer: a review of the current literature","volume":"18","author":"Durrani","year":"2024","journal-title":"Curr. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40164-023-00428-9","article-title":"Inhibition of CDC20 potentiates anti-tumor immunity through facilitating GSDME-mediated pyroptosis in prostate cancer","volume":"12","author":"Wu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clgc.2016.08.018","article-title":"Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH","volume":"15","author":"Moreira","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib6","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/CU9.0000000000000120","article-title":"Androgen receptor signaling-mitochondrial DNA-oxidative phosphorylation: a critical triangle in early prostate cancer","volume":"16","author":"Sakellakis","year":"2022","journal-title":"Curr. Urol."},{"issue":"7035","key":"10.1016\/j.biopha.2025.117955_bib7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"7035","key":"10.1016\/j.biopha.2025.117955_bib8","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"issue":"16","key":"10.1016\/j.biopha.2025.117955_bib9","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.biopha.2025.117955_bib10","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jtho.2017.03.023","article-title":"A novel BRCA1-associated protein-1 isoform affects response of mesothelioma cells to drugs impairing BRCA1-mediated DNA repair","volume":"12","author":"Parrotta","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2025.117955_bib11","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib12","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-021-01061-x","article-title":"Prostate cancer and PARP inhibitors: progress and challenges","volume":"14","author":"Teyssonneau","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061849","article-title":"Advances in PARP inhibitors for prostate cancer","volume":"15","author":"Tisseverasinghe","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/jamaoncol.2018.5801","article-title":"Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","volume":"5","author":"Abida","year":"2019","journal-title":"JAMA Oncol."},{"issue":"6349","key":"10.1016\/j.biopha.2025.117955_bib15","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12929-022-00870-7","article-title":"Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors","volume":"29","author":"Chu","year":"2022","journal-title":"J. Biomed. Sci."},{"issue":"14","key":"10.1016\/j.biopha.2025.117955_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15143642","article-title":"Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches","volume":"15","author":"Dilmac","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.biopha.2025.117955_bib18","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"issue":"21","key":"10.1016\/j.biopha.2025.117955_bib19","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1002\/1878-0261.13224","article-title":"Resistance to DNA repair inhibitors in cancer","volume":"16","author":"Baxter","year":"2022","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib20","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.gendis.2023.02.014","article-title":"Mechanism of PARP inhibitor resistance and potential overcoming strategies","volume":"11","author":"Fu","year":"2024","journal-title":"Genes Dis."},{"issue":"15","key":"10.1016\/j.biopha.2025.117955_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158125","article-title":"The molecular mechanisms of actions, effects, and clinical implications of PARP inhibitors in epithelial ovarian cancers: a systematic review","volume":"23","author":"Lau","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.117955_bib22","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/j.seminoncol.2023.08.001","article-title":"PARP1 roles in DNA repair and DNA replication: the basi(c)s of PARP inhibitor efficacy and resistance","volume":"51","author":"Kanev","year":"2024","journal-title":"Semin Oncol."},{"issue":"27","key":"10.1016\/j.biopha.2025.117955_bib23","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1074\/jbc.TM118.000371","article-title":"How cells ensure correct repair of DNA double-strand breaks","volume":"293","author":"Her","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.117955_bib24","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-biochem-080320-110356","article-title":"Repair of DNA double-strand breaks by the nonhomologous end joining pathway","volume":"90","author":"Stinson","year":"2021","journal-title":"Annu Rev. Biochem"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib25","doi-asserted-by":"crossref","first-page":"7935","DOI":"10.1038\/s41467-024-51457-9","article-title":"RNA-mediated double-strand break repair by end-joining mechanisms","volume":"15","author":"Jeon","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s40164-021-00242-1","article-title":"Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment","volume":"10","author":"Valikhani","year":"2021","journal-title":"Exp. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2025.117955_bib27","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41571-021-00532-x","article-title":"Understanding and overcoming resistance to PARP inhibitors in cancer therapy","volume":"18","author":"Dias","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"issue":"8007","key":"10.1016\/j.biopha.2025.117955_bib29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ijc.33306","article-title":"Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer","volume":"148","author":"Slootbeek","year":"2021","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib31","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clgc.2022.06.016","article-title":"The prognostic significance of homologous recombination repair pathway alterations in metastatic hormone sensitive prostate cancer","volume":"20","author":"Lee","year":"2022","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib32","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur. Urol."},{"issue":"7","key":"10.1016\/j.biopha.2025.117955_bib33","doi-asserted-by":"crossref","first-page":"e1042","DOI":"10.1634\/theoncologist.2019-0495","article-title":"Prognostic value of germline DNA repair gene mutations in De Novo metastatic and castration-sensitive prostate cancer","volume":"25","author":"Wei","year":"2020","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib34","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1200\/JCO.23.00339","article-title":"Olaparib for the treatment of patients with metastatic castration-resistant prostate cancer and alterations in BRCA1 and\/or BRCA2 in the PROfound trial","volume":"42","author":"Mateo","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.117955_bib35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol."},{"issue":"24","key":"10.1016\/j.biopha.2025.117955_bib36","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2025.117955_bib37","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2025.117955_bib38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","article-title":"Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial","volume":"23","author":"Smith","year":"2022","journal-title":"Lancet Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2025.117955_bib39","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.117955_bib40","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(21)00376-4","article-title":"Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial","volume":"22","author":"de Bono","year":"2021","journal-title":"Lancet Oncol."},{"issue":"10398","key":"10.1016\/j.biopha.2025.117955_bib41","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"6330","key":"10.1016\/j.biopha.2025.117955_bib42","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"43","key":"10.1016\/j.biopha.2025.117955_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_390876","article-title":"Managing adverse effects associated with poly (ADP-ribose) polymerase inhibitors in ovarian cancer: a synthesis of clinical trial and real-world data","author":"Friedlander","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib44","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.annonc.2022.02.222","article-title":"The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2\/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Francis","year":"2022","journal-title":"Ann. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib46","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","article-title":"PARP inhibitors: enhancing efficacy through rational combinations","volume":"129","author":"Bhamidipati","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib47","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1080\/14737140.2018.1419870","article-title":"The development of PARP as a successful target for cancer therapy","volume":"18","author":"Ferrara","year":"2018","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib48","doi-asserted-by":"crossref","first-page":"e115","DOI":"10.1634\/theoncologist.2020-0697","article-title":"PARP inhibitors and prostate cancer: to infinity and beyond BRCA","volume":"26","author":"Risdon","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2025.117955_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/PO.21.00152","article-title":"PARP inhibition in prostate cancer with homologous recombination repair alterations","author":"von Werdt","year":"2021","journal-title":"JCO Precis Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib51","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/CU9.0000000000000222","article-title":"Prostate cancer genotyping for risk stratification and precision treatment","volume":"18","author":"Kumar","year":"2024","journal-title":"Curr. Urol."},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib53","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.biopha.2025.117955_bib54","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.2147\/OTT.S315170","article-title":"Clinical utility of olaparib in the treatment of metastatic castration-resistant prostate cancer: a review of current evidence and patient selection","volume":"14","author":"LeVee","year":"2021","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.biopha.2025.117955_bib55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejca.2022.04.016","article-title":"Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: further analyses from the PROfound study","volume":"170","author":"Roubaud","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"16","key":"10.1016\/j.biopha.2025.117955_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163888","article-title":"BRCA mutations in ovarian and prostate cancer: bench to bedside","volume":"14","author":"Boussios","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.biopha.2025.117955_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2023.105397","article-title":"ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification","volume":"299","author":"Rouleau-Turcotte","year":"2023","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.biopha.2025.117955_bib58","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1080\/15384101.2015.1085137","article-title":"Replication-induced DNA damage after PARP inhibition causes G2 delay, and cell line-dependent apoptosis, necrosis and multinucleation","volume":"14","author":"Dale Rein","year":"2015","journal-title":"Cell Cycle"},{"issue":"8","key":"10.1016\/j.biopha.2025.117955_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082054","article-title":"PARP inhibitor resistance mechanisms and implications for post-progression combination therapies","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2025.117955_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114109","article-title":"Recent advances in DDR (DNA damage response) inhibitors for cancer therapy","volume":"230","author":"Cheng","year":"2022","journal-title":"Eur. J. Med Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib61","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.molcel.2012.05.052","article-title":"Quantitative live cell imaging reveals a gradual shift between DNA repair mechanisms and a maximal use of HR in mid S phase","volume":"47","author":"Karanam","year":"2012","journal-title":"Mol. Cell"},{"issue":"38","key":"10.1016\/j.biopha.2025.117955_bib62","doi-asserted-by":"crossref","first-page":"22931","DOI":"10.1074\/jbc.R115.675942","article-title":"DNA end resection: nucleases team up with the right partners to initiate homologous recombination","volume":"290","author":"Cejka","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib63","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1101\/gad.2021311","article-title":"Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications","volume":"25","author":"Polo","year":"2011","journal-title":"Genes Dev."},{"issue":"17","key":"10.1016\/j.biopha.2025.117955_bib64","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1073\/pnas.0811159106","article-title":"PALB2 is an integral component of the BRCA complex required for homologous recombination repair","volume":"106","author":"Sy","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib65","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1139\/bcb-2016-0012","article-title":"Novel insights into RAD51 activity and regulation during homologous recombination and DNA replication","volume":"94","author":"Godin","year":"2016","journal-title":"Biochem Cell Biol."},{"key":"10.1016\/j.biopha.2025.117955_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1354427","article-title":"BRCA1\/2 alterations and reversion mutations in the area of PARP inhibitors in high grade ovarian cancer: state of the art and forthcoming challenges","volume":"14","author":"Collet","year":"2024","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2025.117955_bib67","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev-cancerbio-030617-050502","article-title":"Homology-directed repair and the Role of BRCA1, BRCA2, and related proteins in genome integrity and cancer","volume":"2","author":"Chen","year":"2018","journal-title":"Annu Rev. Cancer Biol."},{"issue":"9","key":"10.1016\/j.biopha.2025.117955_bib68","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/2159-8290.CD-17-0146","article-title":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","volume":"7","author":"Quigley","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib69","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.annonc.2020.10.470","article-title":"A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","volume":"32","author":"Tobalina","year":"2021","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib70","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.annonc.2024.01.003","article-title":"Longitudinal profiling identifies co-occurring BRCA1\/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor-resistant advanced breast cancer","volume":"35","author":"Harvey-Jones","year":"2024","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2025.117955_bib71","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/2159-8290.CD-19-1485","article-title":"Clinical BRCA1\/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance","volume":"10","author":"Pettitt","year":"2020","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061420","article-title":"PARP inhibitors resistance: mechanisms and perspectives","volume":"14","author":"Giudice","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib73","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13148-024-01781-0","article-title":"BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer","volume":"16","author":"Fiegl","year":"2024","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.biopha.2025.117955_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231220511","article-title":"The role of aberrant DNA methylation in cancer initiation and clinical impacts","volume":"16","author":"Geissler","year":"2024","journal-title":"Ther. Adv. Med Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib76","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"issue":"42","key":"10.1016\/j.biopha.2025.117955_bib77","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.biopha.2025.117955_bib78","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1080\/15384047.2019.1595279","article-title":"Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition","volume":"20","author":"Gabbasov","year":"2019","journal-title":"Cancer Biol. Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib79","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1080\/02699931.2021.1891863","article-title":"Testing a computational model of subjective well-being: a preregistered replication of Rutledge et al. (2014)","volume":"35","author":"Vanhasbroeck","year":"2021","journal-title":"Cogn. Emot."},{"issue":"7732","key":"10.1016\/j.biopha.2025.117955_bib80","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41586-018-0670-5","article-title":"DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells","volume":"563","author":"He","year":"2018","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.biopha.2025.117955_bib81","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s12276-020-00519-1","article-title":"DNA end resection and its role in DNA replication and DSB repair choice in mammalian cells","volume":"52","author":"Zhao","year":"2020","journal-title":"Exp. Mol. Med"},{"issue":"49","key":"10.1016\/j.biopha.2025.117955_bib82","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2214935119","article-title":"CCAR2 functions downstream of the Shieldin complex to promote double-strand break end-joining","volume":"119","author":"Iyer","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib83","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrm3719","article-title":"Double-strand break repair: 53BP1 comes into focus","volume":"15","author":"Panier","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.biopha.2025.117955_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114538","article-title":"Identification of the main barriers to Ku accumulation in chromatin","volume":"43","author":"Bossaert","year":"2024","journal-title":"Cell Rep."},{"issue":"49","key":"10.1016\/j.biopha.2025.117955_bib85","doi-asserted-by":"crossref","first-page":"18597","DOI":"10.1073\/pnas.0609061103","article-title":"Dynamic assembly of end-joining complexes requires interaction between Ku70\/80 and XRCC4","volume":"103","author":"Mari","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib86","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/ncb1591","article-title":"Positional stability of single double-strand breaks in mammalian cells","volume":"9","author":"Soutoglou","year":"2007","journal-title":"Nat. Cell Biol."},{"issue":"19","key":"10.1016\/j.biopha.2025.117955_bib87","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1038\/emboj.2010.193","article-title":"Ku prevents Exo1 and Sgs1-dependent resection of DNA ends in the absence of a functional MRX complex or Sae2","volume":"29","author":"Mimitou","year":"2010","journal-title":"Embo J."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib88","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/sj.embor.7401137","article-title":"Ku recruits XLF to DNA double-strand breaks","volume":"9","author":"Yano","year":"2008","journal-title":"EMBO Rep."},{"issue":"7292","key":"10.1016\/j.biopha.2025.117955_bib89","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/nature08926","article-title":"Ku is a 5\u2032-dRP\/AP lyase that excises nucleotide damage near broken ends","volume":"464","author":"Roberts","year":"2010","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib90","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/nsmb1088","article-title":"WRN exonuclease structure and molecular mechanism imply an editing role in DNA end processing","volume":"13","author":"Perry","year":"2006","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib91","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13578-023-01117-0","article-title":"MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC","volume":"13","author":"Zhuang","year":"2023","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib92","doi-asserted-by":"crossref","DOI":"10.1186\/s13578-023-01117-0","article-title":"MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC","volume":"13","author":"Zhuang","year":"2023","journal-title":"Cell Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib93","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2019.01.015","article-title":"53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer","volume":"153","author":"Hurley","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.117955_bib94","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1158\/1535-7163.MCT-17-0098","article-title":"Modeling therapy resistance in BRCA1\/2-mutant cancers","volume":"16","author":"Drean","year":"2017","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib95","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","article-title":"Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms","volume":"44","author":"Jain","year":"2025","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.biopha.2025.117955_bib96","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1158\/2159-8290.CD-17-0261","article-title":"Circulating cell-free DNA to guide prostate cancer treatment with PARP inhibition","volume":"7","author":"Goodall","year":"2017","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.biopha.2025.117955_bib97","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1158\/1078-0432.CCR-20-0707","article-title":"Honing in on PARPi response in prostate cancer: from HR pathway to gene-by-gene granularity","volume":"26","author":"Sokolova","year":"2020","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2025.117955_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102650","article-title":"Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: still looking through a dirty glass window?","volume":"121","author":"Incorvaia","year":"2023","journal-title":"Cancer Treat. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib99","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1158\/1078-0432.CCR-15-1348","article-title":"RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"12","key":"10.1016\/j.biopha.2025.117955_bib100","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol. Med"},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib101","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.molcel.2018.11.003","article-title":"The F-box domain-dependent activity of EMI1 regulates PARPi sensitivity in triple-negative breast cancers","volume":"73","author":"Marzio","year":"2019","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.biopha.2025.117955_bib102","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1111\/cas.14201","article-title":"Depletion of DNA damage binding protein 2 sensitizes triple-negative breast cancer cells to poly ADP-ribose polymerase inhibition by destabilizing Rad51","volume":"110","author":"Zhao","year":"2019","journal-title":"Cancer Sci."},{"issue":"21","key":"10.1016\/j.biopha.2025.117955_bib103","doi-asserted-by":"crossref","first-page":"6196","DOI":"10.1158\/0008-5472.CAN-18-1377","article-title":"HORMAD1 is a negative prognostic indicator in lung adenocarcinoma and specifies resistance to oxidative and genotoxic stress","volume":"78","author":"Nichols","year":"2018","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.biopha.2025.117955_bib104","doi-asserted-by":"crossref","first-page":"10879","DOI":"10.1093\/nar\/gkw921","article-title":"Roles for APRIN (PDS5B) in homologous recombination and in ovarian cancer prediction","volume":"44","author":"Couturier","year":"2016","journal-title":"Nucleic Acids Res."},{"issue":"10","key":"10.1016\/j.biopha.2025.117955_bib105","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/nsmb.1915","article-title":"Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination","volume":"17","author":"Buisson","year":"2010","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib106","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.117955_bib107","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP Inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"issue":"18","key":"10.1016\/j.biopha.2025.117955_bib108","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib109","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.molcel.2013.01.002","article-title":"RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection","volume":"49","author":"Chapman","year":"2013","journal-title":"Mol. Cell"},{"issue":"6120","key":"10.1016\/j.biopha.2025.117955_bib110","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1126\/science.1231573","article-title":"53BP1 regulates DSB repair using Rif1 to control 5\u2032 end resection","volume":"339","author":"Zimmermann","year":"2013","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.biopha.2025.117955_bib111","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S1470-2045(17)30682-4","article-title":"Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Bang","year":"2017","journal-title":"Lancet Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2025.117955_bib112","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1038\/s41388-021-01788-4","article-title":"C\/EBP\u03b2 promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer","volume":"40","author":"Tan","year":"2021","journal-title":"Oncogene"},{"issue":"11_ement","key":"10.1016\/j.biopha.2025.117955_bib113","article-title":"Abstract PR014: Genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"83","author":"Tsujino","year":"2023","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib114","doi-asserted-by":"crossref","first-page":"a012583","DOI":"10.1101\/cshperspect.a012583","article-title":"Base excision repair","volume":"5","author":"Krokan","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2025.117955_bib115","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.trecan.2021.08.007","article-title":"Tackling PARP inhibitor resistance","volume":"7","author":"Fugger","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.biopha.2025.117955_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.888810","article-title":"OGG1 inhibition triggers synthetic lethality and enhances the effect of PARP inhibitor olaparib in BRCA1-deficient TNBC cells","volume":"12","author":"Baquero","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.117955_bib117","doi-asserted-by":"crossref","first-page":"a012708","DOI":"10.1101\/cshperspect.a012708","article-title":"Translesion DNA synthesis and mutagenesis in eukaryotes","volume":"5","author":"Sale","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib118","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen"},{"issue":"31","key":"10.1016\/j.biopha.2025.117955_bib119","doi-asserted-by":"crossref","first-page":"26400","DOI":"10.1074\/jbc.M112.380998","article-title":"Multifaceted recognition of vertebrate Rev1 by translesion polymerases \u03b6 and \u03ba","volume":"287","author":"Wojtaszek","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.biopha.2025.117955_bib120","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn1229","article-title":"Translesion DNA synthesis mediates acquired resistance to olaparib plus temozolomide in small cell lung cancer","volume":"8","author":"Stanzione","year":"2022","journal-title":"Sci. Adv."},{"issue":"16","key":"10.1016\/j.biopha.2025.117955_bib121","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1158\/0008-5472.CAN-12-0103","article-title":"MiR-96 downregulates REV1 and RAD51 to promote cellular sensitivity to cisplatin and PARP inhibition","volume":"72","author":"Wang","year":"2012","journal-title":"Cancer Res."},{"issue":"31","key":"10.1016\/j.biopha.2025.117955_bib122","article-title":"KLF5 promotes tumor progression and parp inhibitor resistance in ovarian cancer","volume":"10","author":"Wu","year":"2023","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"31","key":"10.1016\/j.biopha.2025.117955_bib123","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202304638","article-title":"KLF5 promotes tumor progression and parp inhibitor resistance in ovarian cancer","volume":"10","author":"Wu","year":"2023","journal-title":"Adv. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.117955_bib124","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","article-title":"Navigating the DNA methylation landscape of cancer","volume":"37","author":"Nishiyama","year":"2021","journal-title":"Trends Genet."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010006","article-title":"Epigenetic insights on PARP-1 activity in cancer therapy","volume":"15","author":"Pinton","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.biopha.2025.117955_bib126","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1096\/fj.08-123265","article-title":"Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns","volume":"23","author":"Caiafa","year":"2009","journal-title":"Faseb J."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib127","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.onc.1208005","article-title":"Modulation of DNMT1 activity by ADP-ribose polymers","volume":"24","author":"Reale","year":"2005","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.biopha.2025.117955_bib128","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng1426","article-title":"Poly(ADP-ribosyl)ation regulates CTCF-dependent chromatin insulation","volume":"36","author":"Yu","year":"2004","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.biopha.2025.117955_bib129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.molcel.2009.04.001","article-title":"Epigenetic silencing of the p16(INK4a) tumor suppressor is associated with loss of CTCF binding and a chromatin boundary","volume":"34","author":"Witcher","year":"2009","journal-title":"Mol. Cell"},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib130","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.molcel.2013.01.001","article-title":"A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice","volume":"49","author":"Escribano-D\u00edaz","year":"2013","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.biopha.2025.117955_bib131","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102504","article-title":"Clinical landscape of PARP inhibitors in ovarian cancer: molecular mechanisms and clues to overcome resistance","volume":"14","author":"Kyo","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.biopha.2025.117955_bib132","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1016\/j.molcel.2022.03.030","article-title":"H3K4 methylation by SETD1A\/BOD1L facilitates RIF1-dependent NHEJ","volume":"82","author":"Bayley","year":"2022","journal-title":"Mol. Cell"},{"issue":"18","key":"10.1016\/j.biopha.2025.117955_bib133","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1158\/0008-5472.CAN-21-0774","article-title":"Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high-grade serous ovarian carcinoma","volume":"81","author":"Nesic","year":"2021","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/genes15060750","article-title":"Epigenetic and genomic hallmarks of PARP-inhibitor resistance in ovarian cancer patients","volume":"15","author":"Senturk Kirmizitas","year":"2024","journal-title":"Genes (Basel)"},{"issue":"11","key":"10.1016\/j.biopha.2025.117955_bib135","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1002\/mc.23610","article-title":"Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma","volume":"62","author":"Bitler","year":"2023","journal-title":"Mol. Carcinog."},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib136","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.molcel.2020.08.018","article-title":"PCAF-mediated histone acetylation promotes replication fork degradation by MRE11 and EXO1 in BRCA-deficient cells","volume":"80","author":"Kim","year":"2020","journal-title":"Mol. Cell"},{"issue":"20","key":"10.1016\/j.biopha.2025.117955_bib137","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15204976","article-title":"Histone and DNA methylation as epigenetic regulators of DNA damage repair in gastric cancer and emerging therapeutic opportunities","volume":"15","author":"De Marco","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib138","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41698-021-00189-w","article-title":"PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer","volume":"5","author":"Li","year":"2021","journal-title":"NPJ Precis Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2025.117955_bib139","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/path.4140","article-title":"Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor","volume":"229","author":"Barber","year":"2013","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189033","article-title":"Targeting tumor and bone microenvironment: novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis","volume":"1879","author":"Li","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib141","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12929-024-01099-2","article-title":"Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects","volume":"32","author":"Cao","year":"2025","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.biopha.2025.117955_bib142","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-69194-7_3","article-title":"Leukemia stem cells microenvironment","volume":"1041","author":"Tabe","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib143","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1093\/nar\/gkac073","article-title":"RAD51 protects against nonconservative DNA double-strand break repair through a nonenzymatic function","volume":"50","author":"So","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2025.117955_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216759","article-title":"Exosomal circRNAs: novel biomarkers and therapeutic targets for urinary tumors","volume":"588","author":"Liu","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2025.117955_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100937","article-title":"Exosomal circular RNAs: a chief culprit in cancer chemotherapy resistance","volume":"67","author":"Guo","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib146","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.117955_bib147","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030801","article-title":"Co-inhibition of androgen receptor and PARP as a novel treatment paradigm in prostate cancer-where are we now?","volume":"14","author":"Rao","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib148","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib149","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1016\/j.euo.2024.03.006","article-title":"Tolerability of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: further results from the phase 3 PROpel trial","volume":"7","author":"Saad","year":"2024","journal-title":"Eur. Urol. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.117955_bib150","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid."},{"issue":"9","key":"10.1016\/j.biopha.2025.117955_bib151","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.biopha.2025.117955_bib152","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1200\/JCO.22.01649","article-title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer","volume":"41","author":"Chi","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9040392","article-title":"Changing the history of prostate cancer with new targeted therapies","volume":"9","author":"Hernando Polo","year":"2021","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.biopha.2025.117955_bib154","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1021\/acs.jmedchem.9b02008","article-title":"Design and synthesis of a trifunctional molecular system \u201cProgrammed\u201d to block epidermal growth factor receptor tyrosine kinase, induce high levels of DNA damage, and inhibit the DNA repair enzyme (Poly(ADP-ribose) polymerase) in prostate cancer cells","volume":"63","author":"Schmitt","year":"2020","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib155","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-20-2483","article-title":"Attenuation of SRC kinase activity augments PARP inhibitor-mediated synthetic lethality in BRCA2-altered prostate tumors","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib156","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1158\/1078-0432.CCR-20-2483","article-title":"Attenuation of SRC kinase activity augments PARP inhibitor\u2013mediated synthetic lethality in BRCA2-altered prostate tumors","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib157","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/pros.23741","article-title":"Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram","volume":"79","author":"Majera","year":"2019","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib158","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.biopha.2025.117955_bib159","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1158\/1535-7163.MCT-20-0932","article-title":"CX-5461 sensitizes DNA damage repair\u2013proficient castrate-resistant prostate cancer to PARP inhibition","volume":"20","author":"Lawrence","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib160","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.eururo.2018.06.020","article-title":"Patient-derived models of abiraterone- and enzalutamide-resistant prostate cancer reveal sensitivity to ribosome-directed therapy","volume":"74","author":"Lawrence","year":"2018","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib161","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2025.117955_bib162","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41388-024-02939-z","article-title":"Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer","volume":"43","author":"Chao","year":"2024","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib163","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.21.02947","article-title":"Randomized trial of olaparib with or without cediranib for metastatic castration-resistant prostate cancer: the results from National Cancer Institute 9984","volume":"41","author":"Kim","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"492","key":"10.1016\/j.biopha.2025.117955_bib164","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib165","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13010079","article-title":"ATM kinase inhibition preferentially sensitises PTEN-deficient prostate tumour cells to ionising radiation","volume":"13","author":"Hanna","year":"2020","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.biopha.2025.117955_bib166","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-14-3502","article-title":"Mechanistic rationale to target PTEN-deficient tumor cells with inhibitors of the DNA damage response kinase ATM","volume":"75","author":"McCabe","year":"2015","journal-title":"Cancer Res."},{"issue":"722","key":"10.1016\/j.biopha.2025.117955_bib167","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adf6732","article-title":"Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer","volume":"15","author":"Yamada","year":"2023","journal-title":"Sci. Transl. Med"},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib168","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ccell.2016.09.002","article-title":"Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents \u2013 a potential therapy for cancer","volume":"30","author":"Muvarak","year":"2016","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166300","article-title":"GLI1-targeting drugs induce replication stress and homologous recombination deficiency and synergize with PARP-targeted therapies in triple negative breast cancer cells","volume":"1868","author":"Mani","year":"2022","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"9","key":"10.1016\/j.biopha.2025.117955_bib170","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.neo.2021.06.010","article-title":"Hedgehog\/GLI1 transcriptionally regulates FANCD2 in ovarian tumor cells: its inhibition induces hr-deficiency and synergistic lethality with PARP inhibition","volume":"23","author":"Mani","year":"2021","journal-title":"Neoplasia"},{"key":"10.1016\/j.biopha.2025.117955_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130117","article-title":"Discovery of dual PARP\/NAMPT inhibitors for the treatment of BRCA wild-type triple-negative breast cancer","volume":"120","author":"Mao","year":"2025","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.biopha.2025.117955_bib172","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29122836","article-title":"Targeting NAD metabolism: rational design, synthesis and in vitro evaluation of NAMPT\/PARP1 dual-target inhibitors as anti-breast cancer agents","volume":"29","author":"Li","year":"2024","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.biopha.2025.117955_bib173","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1158\/1078-0432.CCR-17-2575","article-title":"NAMPT is a potent oncogene in colon cancer progression that modulates cancer stem cell properties and resistance to therapy through Sirt1 and PARP","volume":"24","author":"Lucena-Cacace","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib174","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1038\/s41598-023-30081-5","article-title":"Inhibition of nicotinamide dinucleotide salvage pathway counters acquired and intrinsic poly(ADP-ribose) polymerase inhibitor resistance in high-grade serous ovarian cancer","volume":"13","author":"Sauriol","year":"2023","journal-title":"Sci. Rep."},{"issue":"5-6","key":"10.1016\/j.biopha.2025.117955_bib175","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1101\/gad.334516.119","article-title":"PARP and PARG inhibitors in cancer treatment","volume":"34","author":"Slade","year":"2020","journal-title":"Genes Dev."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib176","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12943-024-02025-8","article-title":"PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2025.117955_bib177","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.celrep.2016.10.077","article-title":"CDK12 inhibition reverses de novo and acquired PARP inhibitor resistance in BRCA wild-type and mutated models of triple-negative breast cancer","volume":"17","author":"Johnson","year":"2016","journal-title":"Cell Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.117955_bib178","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/0008-5472.CAN-17-1494","article-title":"Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer","volume":"78","author":"Carey","year":"2018","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib179","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","article-title":"PARPi Triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness","volume":"79","author":"Shen","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.117955_bib180","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60637","article-title":"PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response","volume":"9","author":"Kim","year":"2020","journal-title":"Elife"},{"key":"10.1016\/j.biopha.2025.117955_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: Exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharm. Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib182","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12943-024-02095-8","article-title":"Programmed death receptor (PD-)1\/PD-ligand (L)1 in urological cancers: the \"all-around warrior\" in immunotherapy","volume":"23","author":"Liu","year":"2024","journal-title":"Mol. Cancer"},{"issue":"22","key":"10.1016\/j.biopha.2025.117955_bib183","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1200\/JCO.23.00233","article-title":"Pembrolizumab plus olaparib for patients with previously treated and biomarker-unselected metastatic castration-resistant prostate cancer: the randomized, open-label, phase III KEYLYNK-010 trial","volume":"41","author":"Antonarakis","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.biopha.2025.117955_bib184","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","article-title":"The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models","volume":"16","author":"Herencia-Ropero","year":"2024","journal-title":"Genome Med."},{"issue":"21","key":"10.1016\/j.biopha.2025.117955_bib186","doi-asserted-by":"crossref","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","article-title":"Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper","volume":"28","author":"Illuzzi","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.117955_bib187","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.cell.2018.03.050","article-title":"DNA repair network analysis reveals shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity","volume":"173","author":"Gupta","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.117955_bib188","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1038\/s41467-018-07855-x","article-title":"The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity","volume":"9","author":"Becker","year":"2018","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.biopha.2025.117955_bib189","doi-asserted-by":"crossref","DOI":"10.3390\/genes15060750","article-title":"Epigenetic and genomic hallmarks of PARP-inhibitor resistance in ovarian cancer patients","volume":"15","author":"Senturk Kirmizitas","year":"2024","journal-title":"Genes"},{"issue":"2","key":"10.1016\/j.biopha.2025.117955_bib190","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225001490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225001490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T02:50:24Z","timestamp":1762311024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":190,"alternative-id":["S0753332225001490"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117955","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deciphering the mechanisms of PARP inhibitor resistance in prostate cancer: Implications for precision medicine","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.117955","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117955"}}